Beta Bionics, Inc. Operating Cash Flow
Beta Bionics, Inc. (BBNX) reported Operating Cash Flow of -$38.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-07-29
- Beta Bionics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$14.62M.
- Beta Bionics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$23.83M.
- Beta Bionics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$8.63M.
- Beta Bionics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$8.73M.
- Beta Bionics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$50.92M.
- Beta Bionics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$48.27M.
- Beta Bionics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$32.45M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$14.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$38.45M 10-Q · filed 2026-07-29 | -$47.08M derived: sum of 3 quarters · filed 2026-07-29 | -$55.81M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | -$23.83M 10-Q · filed 2026-04-21 | -$32.46M derived: sum of 2 quarters · filed 2026-04-21 | -$41.19M derived: sum of 3 quarters · filed 2026-04-21 | -$54.78M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | -$8.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$17.36M derived: sum of 2 quarters · filed 2026-02-24 | -$30.95M derived: sum of 3 quarters · filed 2026-07-29 | -$50.92M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$8.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$22.32M derived: sum of 2 quarters · filed 2026-07-29 | -$42.30M 10-Q · filed 2025-10-28 | -$56.58M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | -$13.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$33.57M 10-Q · filed 2026-07-29 | -$47.85M derived: sum of 3 quarters · filed 2026-07-29 | -$57.46M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | -$19.98M 10-Q · filed 2026-04-21 | -$34.25M derived: sum of 2 quarters · filed 2026-04-21 | -$43.87M derived: sum of 3 quarters · filed 2026-04-21 | -$56.10M derived: sum of 4 quarters · filed 2026-04-21 |
| 2024-12-31 | -$14.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$23.89M derived: sum of 2 quarters · filed 2026-02-24 | -$36.13M derived: sum of 3 quarters · filed 2026-02-24 | -$48.27M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$9.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | -$21.85M derived: sum of 2 quarters · filed 2025-10-28 | -$33.99M 10-Q · filed 2025-10-28 | |
| 2024-06-30 | -$12.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | -$24.38M 10-Q · filed 2025-07-29 | ||
| 2024-03-31 | -$12.14M 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | -$32.45M 10-K/A · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |